ify the underlying mechanisms and factors involved in maintenance of euglycemia or hyperglycemia relapse.
The present study aims to elucidate the factors that are responsible for remission or predict for hyperglycemia relapse after intensive insulin therapy in newly diagnosed type 2 diabetes patients.
Materials and Methods

Subjects
We analyzed the original data of a population of 188 patients with newly diagnosed type 2 diabetes who were hypoglycemic drug naïve and received short term intensive insulin therapy with CSII. This patient population comprises the participants in a study conducted by our center and those enrolled in our center in another study initiated and led by our center. All patients were diagnosed type 2 diabetes accord-was used to assess insulin-processing function of β cell.
Statistical analysis
Statistical analysis was performed with SPSS 13.0 program. Quantitative variables with normal distribution (Age, Body mass index (BMI), FPG, PPG, HbA1c, Total cholesterol (TCh), High density lipoprotein-cholesterol (HDL-c), Low density lipoproteincholesterol (LDL-c), FFA, PI/I) are presented as means ± SDs, whereas skewed variables (Triglyceride (TG), HOMA-IR, HOMA-β, DI, AIR) as medians (interquartile range). Independent T test was applied to compare the differences between remission and nonremission group. Paired sample test was used for the comparison of data before and after intervention. To test for the differences among 3 groups of data, ANOVA was applied. Skewed data was log transformed before statistical analysis. Multivariate Logistic regression was done to evaluate the independent predictor of 12-month remission. Cox proportional hazard analysis was performed to assess the risk level of relapse. Cumulative survivals of remission were calculated in patient groups within different FPG range, and time-to-event distributions were summarized with Kaplan-Meier curves. Statistical significance was set at p<0.05.
The studies were approved by the Medical research and ethic committee of Sun Yat-sen University. All patients signed the written informed consent. The study designs have been described in previous publications [3, 4] .
results
Remission rate
Totally 95 patients suffered hyperglycemia relapse. 62.1% (59/95) of hyperglycemic relapse occurred within the first 3 months after intervention, while 77.9% (74/95) within the first 6 months (Fig. 1) . 93 patients had acheived 12-month euglycemic remission. The remission rates at the third, sixth and twelfth months after CSII were 68.6%, 60.6% and 49.5%, respectively.
Metabolic data, beta cell function and insulin sensitivity
General clinical characteristics and metabolic control of all subjects were shown in Table 1 . Substantial improvements in FPG, PPG, HbA1c, TCh, TG, FFA were obtained both in remission and nonremission patients. The remission group exhibited lower FPG after CSII therapy and FFA while other indices of metaing to WHO diagnostic criteria (1999) in department of endocrinology, first affiliated hospital of Sun Yatsen University from September 2001 to October 2006, received intensive insulin therapy with CSII and maintained excellent glycemic control (defined as fasting blood glucose<6.0mmol/L and postprandial blood glucose<8.0mmol/L) for 2 weeks. The patients were then instructed for life style intervention and followed up for 12 months.
Measurements
Fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), glycosylated hemogroblobin A1c (HbA1c), free fatty acid (FFA), lipid profile, plasma proinsulin and insulin concentration were measured both before CSII and at the day at least 15 hours after insulin cessation with a 10-hour overnight fast. Intravenous glucose tolerance test (IVGTT) with 25g glucose was performed before CSII and after insulin cessation, and serum insulin concentrations before and 1, 2, 4, 6, and 10 minutes after intravenous glucose administration were measured.
Follow up
After 2-week CSII intervention was completed, patients were instructed to continue intervention of diet and physical exercise only and were followed-up monthly during the initial 3 months and at 3-month intervals thereafter. Hyperglycaemia relapse was defined as either FPG>7.0 mmol/L or 2-h PPG>10.0 mmol/L, which was confirmed 1 week later. The time of glycaemic remission was recorded, and patients with hyperglycaemic relapse were treated with oral hypoglycaemic agents or insulin according to guidelines. Patients who maintained optimal glycaemic control for at least 12 months without medication were defined as the remission group and those who relapsed during the 12 months of follow-up as the non-remission group.
Calculations
Homeostatic model assessments (HOMA) were applied to evaluated body insulin resistance Fig. 2 ). Differences in metabolic control, β cell function and insulin sensitivity among groups were explored (Table 3) . PPG, HOMA β, DI, and AIR after CSII exhibited gradual declines with increasing levels of FPG.
Correlation and regression
To evaluate the relationship between the duration of remission and indices of metabolic control, β cell function and insulin sensitivity before and after intervention, Pearson correlation was performed. Significant correlation was noted between the duration of remission and FPG after CSII (r= -0.349, p<0.0001), HOMA-β after CSII (r= 0.214, p =0.048).
Multivariate logistic regression showed that FPG after CSII was independent predictor of hyperglycemic relapse (Odds ratio=1.585, p=0.001, 95%CI (1.210, 2.076)), adjusted for age, gender, BMI.
As multivariate Cox proportional hazards regression demonstrated, compared with the patients with FPG<6.1, risk for hyperglycemia relapse was increased 60% in those with 6.1≤FPG≤7.0 (Hazard ratio=1.60, p=0.049, 95%CI (1.13, 2.64)), and 1.69 folds in those with FPG>7.0 (Hazard ratio=2.69, p<0.0001, 95%CI (1.61, 4.50)). Time to event distribution according to different ranges of FPG after CSII was shown in Fig. 3 . bolic profile were comparable between the two groups.
Marked ameliorations in β cell function and insulin sensitivity, both in remission and nonremission patients, were attained after CSII. Greater improvements in HOMA-β, DI and AIR, other than HOMA-IR, were observed in remission group, while PI/I show similar trend but did not reach statistical significance (Table 2 ).
All patients were stratified into three groups according FPG level measured 15 hours after insulin ces- HOMA-β, DI and AIR after therapy while HOMA-IR in two groups was comparable. In our previous research, long-term euglycemic remission was closely associated with maintenance of β cell function. In the 10-year follow up of the Belfast diet study [8] , the ongoing fall of β cell function closely mirrored the progressive rising of fasting plasma glucose, and secondary dietary failure occurred the earliest in those with the poorest β cell function. Similarly in UKPDS, the increasing failure of monotherapy with sulfonylurea, metformin or insulin to achieve tight glycemic control over the first 9 years following diagnosis of type 2 diabetes was consistent with the progressive decline of β-cell function [9] . Insulin sensitivity, evaluated by HOMA-IR, remained unchanged across the follow-up period in either UKPDS [10] or the Belfast study [8] .
Based on these findings, it could be concluded that β cell function, rather than insulin sensitivity, may be the determinant for long term glycemic control, and hyperglycemic relapse actually represented gradual failure of β cell secreting function. Currently, Hu et al.
[11] found a marked decrease in HOMA-IR after intensive therapy in remission subjects but not in nonremission subjects and claimed that improvement of insulin sensitivity could be important factor that determined remission after intensive hypoglycemic therapy. Since metformin, a classic insulin sensitizer, might be included in their regimen, the discrepancy in the role of improvement of insulin resistance in long term remission could be attributed to different therapeutic regimens. Along with new understanding of the pathogenesis of T2DM in recent years, it is rational to propose that combination of intensive insulin therapy and hypoglycemic drugs that target other pathophysiologic mechanisms may maximize the clinical benefit.
An interesting finding of our analysis was the AIR presentation. AIR in remission subjects at baseline was worse than that in nonremission ones (Table 2) despite similar fasting plasma glucose before CSII in two groups (Table 1) . After equivalent glycemic control by short term intensive insulin therapy (indicated by comparable HbA1c and its reduction in remission and nonremission subjects), much greater recovery in AIR was achieved in remission group. Considering that first phase insulin secretion is the most sensitive marker for hyperglycemia to occur [12] and chronic hyperglycemia hampers first phase insulin secretion [13] , we postulate that the extent of the deleterious effect of glu-
Discussion
The major clinical benefit of short term insulin therapy with CSII in patients with newly diagnosed T2DM is the induction of euglycemia without requirement of antidiabetic agents. As shown by our data (Fig. 1) , the remission time of these patients varied from weeks to 12 months. 39.4% (n=74) of all patients suffered hyperglycemic relapse within 6 months after therapy and 50.5% (n=95) within 12 months totally. In the U.K. Prospective Diabetes Study [5] , all participants received only diet intervention in the first 3 months but 84.2% of them failed to attain their fasting plasma glucose of less than 6 mmol/L. Although direct comparison of our study with the UKPDS data may not be appropriate, it could still be derived, from the apparently different rates of dietary failure between two studies, that intensive insulin therapy with CSII in subjects with newly diagnosed T2DM could significantly ameliorate the therapeutic response to diet interventions.
It is widely held belief [6] that glucotoxicity and lipotoxicity contribute to the progressive loss of β-cell function. In our analysis, FPG, PPG, HbA1c, TG and FFA improved significantly in all patients after days of intervention (Table 1) , indicating rapid elimination of glucotoxicity and lipotoxicity by short term intensive insulin therapy with CSII. Furthermore, CSII offers insulin replacement that best mimics physiologic insulin secreting pattern, providing time and "clean" internal environment for β-cell rest and repair. So it is not surprising that HOMA-β, AIR, DI and PI/I ratio were improved significantly by CSII, indicating amelioration of insulin secreting capacity of β cell both quantitatively and qualitatively.
On the other hand, chronic hyperglycemia per se was also able to induce and aggravate insulin resistance [7] . Relief of chronic hyperglycemia brought a reversal of peripheral insulin resistance. In our subjects, lowering blood glucose was accompanied by concomitant decrease of HOMA-IR, suggesting short term intensive insulin therapy improved insulin sensitivity by correcting hyperglycemia. So we believe that induction of remission in newly diagnosed patients with T2DM by CSII could be attributed to improvement of both β cell function and insulin sensitivity.
In order to clarify the underlying mechanisms responsible for long term remission, we analyzed the clinical characteristics and laboratory parameters. We found that nonremission subjects possessed lower ing power when AIR failed to at a high blood glucose level. Given its easy availability, FPG was a much better parameter in clinical work.
The duration of diabetes would impact β cell function, thus influencing remission. However we did not test the effects of duration of diabetes on remission because it is difficult to determine the accurate duration of disease in each patient. So this is a limitation of our study.
In conclusion, both improvement of β cell function and insulin sensitivity contributed to long term remission after intensive insulin therapy in patients with newly diagnosed T2DM. Residual β cell function, rather than insulin sensitivity, may determine the remission time. Fasting plasma glucose after intensive insulin therapy is a convenient and significant predictor for hyperglycemic relapse. In patients with higher FPG after therapy, more intensive follow up should be applied and supplemental drug therapy be implemented in time.
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No potential conflict of interest to be declared. cose toxicity on β cell might vary in different diabetic individuals, and those, in whom beta cell function was impaired by glucose toxicity more profoundly, would attain greater benefit from correcting hyperglycemia by intensive insulin therapy.
In order to figure out parameters that could early identify subjects who tend to get hyperglycemic relapse, we conducted further analysis. As shown by our data, FPG after CSII was of negative correlation with the duration of remission (r= -0.349), and also an independent predictor for hyperglycemic relapse (OR=1.585). Similar finding was reported in our previous study in another population [14] . Furthermore, when stratified into three subgroups by FPG after CSII at levels of 6.1mmol/L and 7.0mmol/L, both longer remission time (Fig. 2) and lower hyperglycemic relapse risk (Fig. 3) were observed in subgroup with lower blood glucose level. These results suggested that FPG measured after cessation of CSII well predicted hyperglycemic relapse.
Fasting plasma glucose has been reported to predict the new onset of diabetes, even within normal range [15, 16] . The elevations of FPG [17] [18] [19] , within normal range and from normal glucose range to impaired fasting glucose and to diabetic range, are consistent with decline in β cell function relative to insulin sensitivity. A curvilinear relationship between FPG and the relative β cell volume (and presumably the β cell mass) has been reported in human autopsy study [20] . In an animal experiment with streptozotocin-treated adult primates [21] , FPG was found to be associated with residual β cell area. In our patients, FPG after CSII was measured 15 hours after cessation of insulin when glucose homeostasis was maintained solely by patients' own β cell function. Therefore the foundation of the predictive function of FPG seemed to be its representation of β cell function to overcome insulin resistance.
In our previous study [3] , recovery of first-phase insulin secretion was considered partially very helpful in maintaining prolonged near normoglycemia and AIR was responsible for long-term remission. However, first-phase insulin secretion was already blunted in subjects with fasting blood glucose (FBG) ≥5.6 mmol/l and was virtually absent when FBG reached 6.4mmol/l [12] . Therefore, in individuals with high FPG, AIR decreases little even when blood glucose keeps increasing. In these subjects, AIR will lose its predicting function. In our analysis, FPG was continuously correlated with remission time, and still provided predict-
